Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;57(1):57-62.
doi: 10.1007/s00038-011-0266-4. Epub 2011 Jun 17.

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008

Affiliations

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008

Willi Oberaigner et al. Int J Public Health. 2012 Feb.

Abstract

Objectives: The objective of this study was to update an in-depth analysis of the time trend for prostate cancer (PCA) mortality in the population of Tyrol by 5 years, namely to 2008. In Tyrol, prostate-specific antigen (PSA) tests were introduced in 1988/89; more than three-quarters of all men in the age group 45-74 had at least one PSA test in the past decade.

Methods: We applied the same model as in a previous publication, i.e., an age-period-cohort model using Poisson regression, to the mortality data covering more than three decades from 1970 to 2008.

Results: For Tyrol from 2004 to 2008 in the age group 60+ period terms show a significant reduction in prostate cancer mortality with a risk ratio of 0.70 (95% confidence interval 0.57, 0.87) for Tyrol, and for Austria excluding Tyrol a moderate reduction with a risk ratio of 0.92 (95% confidence interval 0.87, 0.97), each compared to the mortality rate in the period 1989-1993.

Conclusions: This update strengthens our previously published results, namely that PSA testing offered to a population at no charge can reduce prostate cancer mortality. The extent of mortality reduction is in line with that reported in the other recent publications. However, our data do not permit us to fully assess the harms associated with PCA screening, and no recommendation for PSA screening can be made without a careful evaluation of overdiagnosis and overtreatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Prostate cancer mortality: age-standardized rate in Tyrol and in Austria excluding Tyrol for years of death 1970–2008 (vertical line is end of previous publication)
Fig. 2
Fig. 2
Prostate cancer mortality in Tyrol and in Austria excluding Tyrol for years of death 1970–2008, age 60+: estimated period effects
Fig. 3
Fig. 3
Prostate cancer incidence: age-standardized rate in Tyrol and in Austria excluding Tyrol for years of diagnosis 1983–2007
Fig. 4
Fig. 4
Prostate cancer mortality in Tyrol and in Austria excluding Tyrol for years of death 1970–2008: result of joinpoint regression for age-specific rate age 60+. Annual percentage change for Tyrol 2.8* (1970–1992), −5.3* (1992–2008) and for Austria excluding Tyrol 3.6* (1970–1978), 1.4* (1978–1991), −0.3 (1991–1999), −3.8* (1999–2006), 2.4 (2006–2008), *denoting statistical significance

Comment in

Similar articles

Cited by

References

    1. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319. doi: 10.1056/NEJMoa0810696. - DOI - PMC - PubMed
    1. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417–424. doi: 10.1016/S0090-4295(01)01264-X. - DOI - PubMed
    1. Bartsch G, Horninger W, Klocker H, et al. Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality. BJU. 2008;101:809–816. doi: 10.1111/j.1464-410X.2008.07502.x. - DOI - PubMed
    1. Boyle P, Brawley O (2009) Prostate Cancer: current evidence weighs against population screening. CA Cancer J Clin 59:220–224 - PubMed
    1. Boyle P, Levin B, editors. World cancer report 2008. Lyon: IARC; 2008.

Publication types

Substances